We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FTC Slams Celgene’s Use of REMS To Block Generics Competition
FTC Slams Celgene’s Use of REMS To Block Generics Competition
The FTC gave generics makers a boost last month in their fight to stop brand drugmakers from using REMS restrictions to block access to sample drugs the generics industry needs to prepare ANDAs.